共 340 条
[1]
King KM(2009)Optimal use of taxanes in metastatic breast cancer Curr Oncol 16 8-20
[2]
Lupichuk S(1995)Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 3-10
[3]
Baig L(2006)RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J Clin Oncol 24 4731-4737
[4]
Webster M(2007)Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer Int J Cancer 120 1355-1363
[5]
Basi S(2002)Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial Oncology 62 2-8
[6]
Whyte D(1999)Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer J Clin Oncol 17 2190-2197
[7]
Rix S(2000)Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines Br J Cancer 83 1069-1976
[8]
Plunkett W(2004)Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain Ann Oncol 15 201-206
[9]
Huang P(2004)Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer Oncology 66 18-23
[10]
Xu YZ(2001)Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer Am J Clin Oncol 24 264-268